Loading...
XSHG
600671
Market cap190mUSD
Apr 11, Last price  
11.40CNY
1D
3.73%
1Q
38.69%
Jan 2017
-63.00%
Name

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
11.40
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
-19.42%
Revenues
217m
+78.44%
238,707,452259,671,298265,228,863253,978,179245,336,892234,226,890277,265,339229,078,895281,468,861148,727,33894,765,832123,725,458176,382,787358,470,846297,072,374206,627,323147,069,186108,906,179121,778,535217,295,933
Net income
15m
P
3,671,008386,43015,120,9894,079,5180026,439,20702,108,4202,713,42801,217,1847,179,075050,680,106000-38,275,14815,245,827
CFO
0k
P
8,482,67555,387,26847,532,66521,189,1807,583,47500012,372,830653,79001,606,84924,520,31970,706,116161,127,708000-20,428,8200
Dividend
Aug 24, 20050.163768 CNY/sh
Earnings
May 20, 2025

Profile

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, slicing, and powder grinding services, as well as Chinese medicine diagnosis and treatment services. In addition, the company engages in the software development, remote health management, commercial complex management, food, Internet information businesses, etc. Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd was founded in 1958 and is headquartered in Hangzhou, China.
URL
http://www.hztmyy.com/
IPO date
Aug 23, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
217,296
78.44%
121,779
11.82%
108,906
-25.95%
Cost of revenue
136,304
115,061
103,758
Unusual Expense (Income)
NOPBT
80,992
6,717
5,148
NOPBT Margin
37.27%
5.52%
4.73%
Operating Taxes
7,207
2,985
842
Tax Rate
8.90%
44.44%
16.36%
NOPAT
73,785
3,732
4,306
Net income
15,246
-139.83%
(38,275)
 
Dividends
(6,665)
Dividend yield
0.47%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
126,887
102,639
108,541
Long-term debt
20,671
14,463
14,926
Deferred revenue
52,634
58,616
65,246
Other long-term liabilities
948
1,148
1,430
Net debt
81,833
19,140
81,075
Cash flow
Cash from operating activities
(20,429)
CAPEX
(8,956)
Cash from investing activities
(8,826)
Cash from financing activities
13,037
84,825
56,056
FCF
19,439
17,006
60,025
Balance
Cash
65,725
97,963
42,392
Long term investments
1
2
2
Excess cash
54,860
91,874
36,947
Stockholders' equity
154,414
(131,021)
191,959
Invested Capital
220,963
356,604
147,781
ROIC
25.55%
1.48%
2.22%
ROCE
28.72%
2.94%
2.79%
EV
Common stock shares outstanding
121,779
121,779
121,779
Price
8.78
-24.64%
11.65
22.50%
9.51
5.90%
Market cap
1,069,219
-24.64%
1,418,726
22.50%
1,158,117
5.90%
EV
1,183,686
1,456,676
1,258,299
EBITDA
99,575
21,731
23,493
EV/EBITDA
11.89
67.03
53.56
Interest
5,561
7,244
7,404
Interest/NOPBT
6.87%
107.84%
143.84%